Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of olaparib plus pembrolizumab in previously treated advanced solid tumors with homologous recombination repair mutations or homologous recombination deficiency
MOH_2019-10-15_007441Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and pembrolizumab in Nonhematologic neoplasms and advanced nonhematological malignancy, sponsored by Merck & Co. Started Sep 2019; status: active, not recruiting.
02
Drugs
olaparibpembrolizumab
03
Conditions
Nonhematologic neoplasmsadvanced nonhematological malignancy
Beyond the preview
Go deeper on MOH_2019-10-15_007441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-15_007441.